Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM) ...

Direct comparative efficacy studies are few, and also may have design issues, which make their interpretation difficult. The most serious safety issues for monoclonal antibodies include the risk ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Advancing its Mission to Combat Respiratory Infectious Diseases SINGAPORE, SINGPORE, SINGAPORE, January 22, 2025 /EINPresswire / -- -C ...

Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...

A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold. The discovery, led by ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...